Approval · Notice of Compliance 23574 · 2020
ACT RIZATRIPTAN: Notice of Compliance 23574
Issued May 6, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23574
- Date
- May 6, 2020
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Merger- buyout. licensing agreement betwee two companies
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT RIZATRIPTAN | 02381699 | Approved |
| ACT RIZATRIPTAN | 02381702 | Marketed |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB